Dravet Syndrome Clinical Trials 2023

What are the top hospitals conducting dravet syndrome research?

In the realm of clinical trials for Dravet Syndrome, a rare and severe form of epilepsy, several hospitals have emerged as leaders in research and treatment. Among them is the NYU Comprehensive Epilepsy Center in New york, which currently has five active trials dedicated to this condition. Although relatively new to studying Dravet Syndrome, with their first trial recorded in 2019, their commitment to advancing knowledge and treatments is evident. Meanwhile, the Children's Hospital of Philadelphia stands tall with four ongoing trials and a total of seven completed studies since embarking on its first Dravet Syndrome trial in 2016. Similarly invested in finding solutions is Seattle Children's Hospital, also boasting four active Dravet Syndrome trials along with an impressive track record of seven previous investigations dating back to 2016.

Further expanding this list is the Children's Hospital Colorado located in Aurora where three ongoing dravet syndrome clinical tests are held while they hold reputation conducting previous five experiments from starting pioneering investigation on such cases way back until2020.Finally,Nicklaus Children's Hospital based out Miami actively engages furthering medical progresses by hosting three current dravetsyndrome clinicaltrialsandcontributing towards paving newpaths throughsix previously held investigations; theirs can be traced back onlythree years ago when they commenced itin 2018.

These renowned institutions not only offer hope for individuals living with Dravet Syndrome but also shed light on the tireless efforts made by researchers around the country. Through these collaborative endeavors and cutting-edge trials, we inch closer to discovering innovative treatments that can alleviate symptoms and improve lives affected by this challenging neurological disorder. The dedication shown by these top hospitals serves as a beacon of optimism for patients worldwide who rely on continued progress within the field

Which are the best cities for dravet syndrome clinical trials?

When it comes to dravet syndrome clinical trials, several cities emerge as key hubs for research. New york, with its 13 active trials, explores treatments like Lorcaserin, Soticlestat, and ZX008 (Fenfluramine Hydrochloride). San Francisco follows closely behind with 8 ongoing studies focused on Soticlestat and STK-001. Philadelphia, Fort Worth, and Seattle each have 6 active trials examining similar treatment options. These cities offer individuals affected by dravet syndrome access to cutting-edge clinical trials that pave the way for advancements in care and potential breakthroughs in managing this challenging condition.

Which are the top treatments for dravet syndrome being explored in clinical trials?

Dravet syndrome, a challenging and often debilitating condition, is the focus of several promising treatments currently being explored in clinical trials. Among them are:

• Soticlestat: With two active trials and three all-time dravet syndrome trials since its introduction in 2018, this treatment shows great potential.
• STK-001: Although still in early stages with one active trial and one all-time dravet syndrome trial as of 2021, research into this therapy holds promise.
• Lorcaserin: Another contender making strides with one ongoing trial and one historical dravet syndrome trial since its first listing in 2020.
• GWP42003-P: Building on previous research efforts, this treatment is involved in one current study alongside three past clinical trials specifically targeting dravet syndrome. Its initial listing dates back to 2015.
• EPX-100 (Clemizole HCl): While at an early stage with only one active trial and one all-time dravet syndrome trial conducted so far since it was listed for investigation in 2020, this therapy demonstrates potential benefits.

These ongoing investigations offer hope for individuals affected by Dravet Syndrome as researchers strive to uncover new solutions that may alleviate symptoms and improve quality of life.

What are the most recent clinical trials for dravet syndrome?

Recent clinical trials hold promise for individuals with Dravet syndrome, a rare and debilitating form of epilepsy. Soticlestat has been the focus of multiple Phase 3 trials, showing potential in managing seizures associated with this condition. Additionally, GWP42003-P and STK-001 have undergone Phase 3 and Phase 2 trials respectively, aiming to provide novel treatment options for Dravet syndrome patients. These groundbreaking studies highlight the ongoing efforts to uncover effective therapies that can improve the quality of life for those affected by this challenging neurological disorder.

What dravet syndrome clinical trials were recently completed?

In June 2016, a significant clinical trial examining the effectiveness of ZX008 (Fenfluramine Hydrochloride) in treating dravet syndrome reached completion. The trial was sponsored by Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. This milestone represents an important step in understanding and potentially improving treatment options for individuals with dravet syndrome.